LuckCong's Health Blog

With the anti-hepatitis B virus in recent years, the constant introduction of new drugs listed, chronic hepatitis B (CHB) treatment effect than 3 years ago has been greatly improved. From 2005 listed one after another in our country Dipivoxil of nucleoside analogues, entecavir, as well as the newly listed this year, telbivudine and lamivudine in the initial together to build a nucleoside analogue treatment of hepatitis B Strong Powerful ammunition depots. In addition, apart from the nucleoside analogues, and those with chronic hepatitis B treatment of the antiviral drug interferon in recent years has also launched a long-acting form of polyethylene glycol, as compared with ordinary further enhance the efficacy of interferon. A few days ago, to be held in South Korea's Cheju Island in emerging markets strategy seminar on the treatment of chronic hepatitis B, liver disease experts in international Auckland, New Zealand, Professor Edward Gane of the proposed treatment of chronic hepatitis B individual optimization of the new strategy, that is, the combination of chronic hepatitis B treatment Road map, on a regular basis to assess the effect of the adjustment of drug treatment programs so as to enhance the treatment of chronic hepatitis B, reducing or even prevent the disease in patients with liver cirrhosis, liver cancer, and other long-term complications. Previously held in Kyoto, Japan in the Asia-Pacific Association for Study of Liver Diseases (APASL) 17th Annual Meeting, attended by international experts in liver disease combined with the treatment of chronic hepatitis B road map, as well as the United States in February by the association for the study of liver disease (AASLD) announced The latest edition of "Guide to hepatitis B prevention and treatment" had a thorough exchange of views. They reached the wishes of one of the principal is: the initial treatment for patients from the very beginning treatment should be preferred anti-virus capability, the low rate of drug resistance. In the recent publication of academic activities, a growing number of studies have shown that the treatment of chronic hepatitis B for example, when a poor effect of drugs (such as six months into the treatment can not effectively minimize the level of hepatitis B virus ), The switch to more antiviral drugs in another, to more effectively suppress the virus, such as the level of the virus less than Inhibition to detect. If the initial treatment and appropriate use of potent anti-viral drugs, to minimize the level is an effective way to promote the resumption of regular transaminase and serum HBeAg conversion, to reduce the incidence of resistance in order to achieve sustained effect. Experts said that the existing 4 nucleoside analogues and interferon agents for the treatment of chronic hepatitis B to address a variety of difficulties, such as poor efficacy, HBeAg negative rate on the low side, the emergence of drug resistance, as well as Security concerns, and so on, provides a wide range of application portfolio means. Doctors can change in patients with specific conditions, the use of individualized treatment. For example, patients with a higher baseline level of hepatitis B virus, hepatitis B virus in the body that is to copy a large number of the option potent anti-viral drugs, such as telbivudine, entecavir; patients, "Dasan Yang", faced with further education, employment, etc. , Will need to HBeAg negative, "Xiao Sanyang," could be considered a higher rate of negative interferon or telbivudine; taking into account the long-term anti-viral treatment of security, not only to consider the option of using a longer time, Application of experience or more nucleoside analogues lamivudine in the United States was the only FDA pregnancy that the B-class telbivudine, or choose a low incidence of drug resistance and side effects of the low incidence of entecavir. Turning to interferon treatment, Gane, a professor pointed out that the treatment of patients with a baseline of a number of conditions, such as age, sex, level of aminotransferase, the level of hepatitis B virus, and so on, the effect of interferon can have a significant effect, this view has been Wide range of academic accreditation. The application of nucleoside analogues in the treatment of chronic hepatitis B clinical study results showed that telbivudine treatment, "Dasan Yang," The patients in the treatment of baseline level of aminotransferase is greater than twice the normal patients, a better effect; drug Six months can reach 49% of patients with hepatitis B virus detection level of less than; treatment for two years, 86% of patients with hepatitis B virus levels remain negative, 49% of patients achieved a "Dasan Yang" to the "Three Yang ", 85% of the patients with normal transaminase. Based on a number of recent studies, as well as relevant guidelines of the view that for the hepatitis B virus genotype A and Type D patients, interferon is superior to the effect on B-and C-type patients; patients with genotype of nucleoside Analogues did not affect the basic effect. In addition, although chronic hepatitis B require long-term anti-viral treatment, but "Dasan Yang" and the treatment of patients, "Xiao Sanyang," and patients are different, so if you need long-term treatment, the drug's long-term security must be considered as a One of the important factors; the treatment of choice in the process of potent drugs can quickly detect the virus less than Inhibition, and the high rate of the e antigen negative / conversion rate is the attending doctor must first focus of attention.